MX2023005990A - Agente terapeutico antitumoral que migra al cerebro, que contiene como ingrediente activo un compuesto de pirimidina fusionada. - Google Patents
Agente terapeutico antitumoral que migra al cerebro, que contiene como ingrediente activo un compuesto de pirimidina fusionada.Info
- Publication number
- MX2023005990A MX2023005990A MX2023005990A MX2023005990A MX2023005990A MX 2023005990 A MX2023005990 A MX 2023005990A MX 2023005990 A MX2023005990 A MX 2023005990A MX 2023005990 A MX2023005990 A MX 2023005990A MX 2023005990 A MX2023005990 A MX 2023005990A
- Authority
- MX
- Mexico
- Prior art keywords
- brain
- sup
- active ingredient
- therapeutic agent
- agent containing
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- -1 pyrimidine compound Chemical class 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un objeto que la presente invención intenta resolver es proveer un agente antitumoral que penetre el cerebro y que muestre una excelente propiedad de penetración cerebral; la presente invención provee un agente antitumoral que penetra el cerebro que incluye como ingrediente activo un compuesto representado por la fórmula (I) siguiente o una sal del mismo: (ver Fórmula) (I) en donde R1, R2 y R3 son como se describe en la especificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020193073 | 2020-11-20 | ||
| PCT/JP2021/042502 WO2022107864A1 (ja) | 2020-11-20 | 2021-11-18 | 縮合ピリミジン化合物を有効成分とする脳移行性腫瘍治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005990A true MX2023005990A (es) | 2023-06-07 |
Family
ID=81709080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005990A MX2023005990A (es) | 2020-11-20 | 2021-11-18 | Agente terapeutico antitumoral que migra al cerebro, que contiene como ingrediente activo un compuesto de pirimidina fusionada. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240025910A1 (es) |
| EP (1) | EP4248974A1 (es) |
| JP (1) | JPWO2022107864A1 (es) |
| KR (1) | KR20230110558A (es) |
| CN (1) | CN116744930A (es) |
| AU (1) | AU2021384158A1 (es) |
| CA (1) | CA3199714A1 (es) |
| MX (1) | MX2023005990A (es) |
| TW (1) | TW202227450A (es) |
| WO (1) | WO2022107864A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3269370T2 (ro) | 2016-02-23 | 2020-05-31 | Taiho Pharmaceutical Co Ltd | Compus pirimidinic condensat nou sau sare a acestuia |
| JP2019182806A (ja) * | 2018-04-16 | 2019-10-24 | 塩野義製薬株式会社 | 二環性複素環誘導体およびそれらを含有する医薬組成物 |
| JP7311944B2 (ja) * | 2018-04-16 | 2023-07-20 | 塩野義製薬株式会社 | 二環性含窒素複素環誘導体を含有する医薬組成物 |
| DK3909584T3 (da) * | 2019-01-11 | 2024-01-15 | Taiho Pharmaceutical Co Ltd | Pyrimidinforbindelse eller salt deraf |
| JP7334471B2 (ja) | 2019-05-28 | 2023-08-29 | セイコーエプソン株式会社 | 媒体整合装置、媒体処理装置、及び記録システム |
-
2021
- 2021-11-18 US US18/253,273 patent/US20240025910A1/en active Pending
- 2021-11-18 KR KR1020237020608A patent/KR20230110558A/ko unknown
- 2021-11-18 WO PCT/JP2021/042502 patent/WO2022107864A1/ja active Application Filing
- 2021-11-18 CA CA3199714A patent/CA3199714A1/en active Pending
- 2021-11-18 JP JP2022563833A patent/JPWO2022107864A1/ja active Pending
- 2021-11-18 EP EP21894736.4A patent/EP4248974A1/en active Pending
- 2021-11-18 TW TW110143064A patent/TW202227450A/zh unknown
- 2021-11-18 MX MX2023005990A patent/MX2023005990A/es unknown
- 2021-11-18 CN CN202180090476.7A patent/CN116744930A/zh active Pending
- 2021-11-18 AU AU2021384158A patent/AU2021384158A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116744930A (zh) | 2023-09-12 |
| WO2022107864A1 (ja) | 2022-05-27 |
| KR20230110558A (ko) | 2023-07-24 |
| AU2021384158A2 (en) | 2023-10-12 |
| AU2021384158A1 (en) | 2023-06-22 |
| EP4248974A1 (en) | 2023-09-27 |
| JPWO2022107864A1 (es) | 2022-05-27 |
| TW202227450A (zh) | 2022-07-16 |
| US20240025910A1 (en) | 2024-01-25 |
| CA3199714A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009187A (es) | Compuesto de quinazolina. | |
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| PH12018501716A1 (en) | Novel condensed pyrimidine compoun or salt thereof | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| NZ739893A (en) | Fused pyrimidine compound or salt thereof | |
| MX2007003603A (es) | Metodos para preparar compuestos de indazol. | |
| MX2022007130A (es) | Derivados de piperazina sustituidos utiles como activadores de celulas t. | |
| MX2022007369A (es) | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
| PH12020551624A1 (en) | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | |
| MX2021015969A (es) | Compuestos heterocíclicos para mediar la actividad de la tirosina cinasa 2. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| MX2023009379A (es) | Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer. | |
| MX2023009285A (es) | Compuestos novedosos. | |
| MX2023005990A (es) | Agente terapeutico antitumoral que migra al cerebro, que contiene como ingrediente activo un compuesto de pirimidina fusionada. | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| MX2021008071A (es) | Derivados de imidazol fusionado sustituido y métodos de tratamiento de la anemia de células falciformes y complicaciones relacionadas. |